Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 3/20 | 1.00 |
| ▸ | FBP1 | P09467 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444884 | 1.00 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL30363011 | 1.00 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL29369196 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL93918 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| Hydrochloric Acid SCHEMBL30362813 | 0.99 | EGFR (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL12963484 | 0.93 | FBP1 (0.91) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL8349430 | 0.92 | EGFR (0.91) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL4232360 | 0.91 | FBP1 (0.84) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL22367416 | 0.91 | FBP1 (1.00) | EGFRKDRERBB2FBP1SRC | |
| SCHEMBL4229994 | 0.90 | EGFR (0.82) | EGFRKDRERBB2FBP1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| CN-115490640-B | Substituted benzimidazoles, compositions containing them and their use | 深圳市塔吉瑞生物医药有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-08-01 | — | — | US | claimed |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | UNITED STATES GOVERNMENT | 2024-07-25 | — | — | US | claimed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4334290-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | The University of British Columbia (CA) | 2024-03-13 | — | — | EP | claimed |
| EP-4330224-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | City of Hope (US) | 2024-03-06 | — | — | EP | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| EP-1163228-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | claimed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| US-6004967-A | TOPICALLY ADMINISTERING 4-(3-BROMOPHENYLAMINO)-6,7-DIMETHOXYQUINAZOLINE TO TREAT HYPERPROLIFERATION CAUSED BY PAPILLOMAVIRUS INFECTION | SUGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | PCNA, MKI67, EGFR | EGFR 3/4885KDR 308/4885ERBB2 19/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885KDR 3004/4885ERBB2 730/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | EGFR 285/4885KDR 3015/4885ERBB2 523/4885 |
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | RXFP3, SLC39A3, NR4A3 | EGFR 122/4885KDR 255/4885ERBB2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.